A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.

Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, Lai Z, Raj GV, Yuan Y, Zhou D, Sareddy GR, Tekmal RR, McHardy S, Huang TH, Rao MK, Vankayalapati H, Vadlamudi RK

Open source

DOI: 10.1158/0008-5472.can-22-0698
Published: 2022 Oct 17
Container: Cancer research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/0008-5472.can-22-0698,
  title = {A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.},
  author = {Altwegg KA and Viswanadhapalli S and Mann M and Chakravarty D and Krishnan S and Liu Z and Liu J and Pratap UP and Ebrahimi B and Sanchez JR and Li X and Ma S and Park BH and Santhamma B and Chen Y and Lai Z and Raj GV and Yuan Y and Zhou D and Sareddy GR and Tekmal RR and McHardy S and Huang TH and Rao MK and Vankayalapati H and Vadlamudi RK},
  year = {2022},
  journal = {Cancer research},
  doi = {10.1158/0008-5472.can-22-0698},
  url = {https://doi.org/10.1158/0008-5472.can-22-0698}
}

RIS

TY  - JOUR
TI  - A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
AU  - Altwegg KA
AU  - Viswanadhapalli S
AU  - Mann M
AU  - Chakravarty D
AU  - Krishnan S
AU  - Liu Z
AU  - Liu J
AU  - Pratap UP
AU  - Ebrahimi B
AU  - Sanchez JR
AU  - Li X
AU  - Ma S
AU  - Park BH
AU  - Santhamma B
AU  - Chen Y
AU  - Lai Z
AU  - Raj GV
AU  - Yuan Y
AU  - Zhou D
AU  - Sareddy GR
AU  - Tekmal RR
AU  - McHardy S
AU  - Huang TH
AU  - Rao MK
AU  - Vankayalapati H
AU  - Vadlamudi RK
PY  - 2022
JO  - Cancer research
DO  - 10.1158/0008-5472.can-22-0698
UR  - https://doi.org/10.1158/0008-5472.can-22-0698
ER  -

APA

KA, A., S, V., M, M., D, C., S, K., Z, L., J, L., UP, P., B, E., JR, S., X, L., S, M., BH, P., B, S., Y, C., Z, L., GV, R., Y, Y., D, Z., GR, S., RR, T., S, M., TH, H., MK, R., H, V., & RK, V. (2022). A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.. Cancer research. https://doi.org/10.1158/0008-5472.can-22-0698

Source records

pubmed · retrieved 2026-09-27T11:51:57.102Z